Concepedia

Vithika Suri

VS

Statistics

Publications

28

Citations

1.8K

H-Index

18

Active since

2008

Affiliations

Gilead Sciences (United States)(Current)

Hôpital Beaujon

Medizinische Hochschule Hannover

University of Milan

Chinese University of Hong Kong

Vithika Suri is an author at Gilead Sciences (United States) specializing in viral hepatitis, antiviral therapy, and viral hepatitis treatment.

Publications per year

2008–2024

28

Publications

28

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

Kosh Agarwal, Maurizia Rossana Brunetto, Wai Kay Seto et al. · Journal of Hepatology · 2018 · 423 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +10

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Rong Fan, George Papatheodoridis, Jian Sun et al. · Journal of Hepatology · 2020 · 349 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto et al. · New England Journal of Medicine · 2023 · 215 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +13

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Pietro Lampertico, Scott Fung, Sang Hoon Ahn et al. · The Lancet. Gastroenterology & hepatology · 2020 · 139 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

Catherine A. Chappell, Kimberly K. Scarsi, Brian Kirby et al. · The Lancet Microbe · 2020 · 111 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

1–5 of 28